What's in Geron Corporation's pipeline?

Geron Corporation has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Geron Corporation's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/geron.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Geron Corporation — Portfolio Competitive Intelligence Brief

Geron Corporation (GERN) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

GERN (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rytelo	IMETELSTAT	marketed			Oncology	2024-01-01

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

2026-04-14 — Rytelo · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Geron Corporation:

Cite this brief

Drug Landscape (2026). Geron Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/geron. Accessed 2026-05-13.